Clinical Trials Using WT1 Protein-derived Peptide Vaccine DSP-7888

Clinical trials are research studies that involve people. The clinical trials on this list are studying WT1 Protein-derived Peptide Vaccine DSP-7888. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

    This is a Phase 1b / 2, open-label, multicenter study of DSP-7888 in combination with checkpoint inhibitors (nivolumab or pembrolizumab) in adult patients with solid tumors, that consists of 2 parts: dose search part of the study (Phase 1b) and the dose expansion part of the study (Phase 2). In Phase 1b of this study there will be 2 arms: Arm 1 and Arm 2. In Arm 1, there will be 6 to 12 patients who will be dosed with DSP-7888 and nivolumab and in Arm 2 there will be 6 to 12 patients who will be dosed with DSP-7888 and pembrolizumab. Once the recommended dose is determined in Phase 1b, platinum-resistant ovarian cancer (PROC) patients will be enrolled in Phase 2 of the study with DSP-7888, exploring the combination with pembrolizumab (Arm 2). In Phase 2, approximately 40 patients with PROC will be initially enrolled.
    Location: 5 locations